In this study, the investigators are testing improvement in survival outcomes in DIPG patients when stratified with MR perfusion score and treated with the said protocol. Newly diagnosed DIPG patients will undergo MRI perfusion study in addition to the usual MRI at diagnosis and will be stratified into hyperperfused or hypoperfused tumours.
The hyperperfused patients will receive additional low dose Bevacizumab weekly with conventional standard radiotherapy.
The hypo-perfused patients will receive ultra-low-dose radiotherapy fractionation equivalent to conventional RT biological dose.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2020-01-30; most recent amendment 2025-04-08.
Status change: Not Yet Recruiting → Recruiting2020-03-20